Search results
AstraZeneca pulls its COVID-19 vaccine from Europe
Boston Herald· 7 days agoThe pharma giant AstraZeneca has requested that the European authorization for its COVID-19 vaccine be pulled, according to the EU medicines regulator....
The doctor behind the next big thing in cancer treatment
CNN via Yahoo News· 7 days agoDr Catherine Wu’s research has laid the scientific foundation for the development of cancer vaccines...
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 6 days agoMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q1 2024 Earnings Call Transcript May 9, 2024 Matinas...
Moderna’s First Vaccine Was a Big Hit. Its Second Is a Let Down
Bloomberg via Yahoo Finance· 7 days ago(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion...
Novavax Stock Surges 140% on $1.4 Billion Deal With Sanofi
Barrons.com· 6 days agoNovavax the pharmaceutical company that last year warned that falling sales of its Covid-19 vaccine...
Novavax stock doubles after Sanofi deal marks 'new chapter' for company
Yahoo Finance· 6 days agoNovavax struggled after its COVID-19 vaccine was delayed by manufacturing issues early in...
Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
WJTV Jackson· 1 day agoTotal operating revenues in Q1 2024 amounted to $6.4M, compared to $4.3M in Q1 2023. As of May 9, 2024, Ryvu's cash position was $59.0M, inclusive of the first tranche of €8M in venture debt ...
National Academies Report: COVID-19 Vaccines Don’t Cause Many Potential Harms
Journal of the American Medical Association· 6 days agoThe COVID-19 vaccines made by Pfizer-BioNTech and Moderna do not cause such conditions as female infertility, myocardial infarction, Bell palsy, or Guillain-Barré syndrome ...
Novavax Soars on $1.2 Billion Sanofi Vaccine Licensing Deal
Bloomberg via Yahoo Finance· 6 days ago(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 2 days agoSales also tumbled 20% to $14.88 billion, but topped forecasts for $13.87 billion. As expected,...